Last updated: January 20, 2026
Executive Summary
Keveyis (dichlorphenamide) is a drug approved by the FDA in 2015 for the treatment of primary hyperkalemic and hypokalemic periodic paralysis. It represents a niche therapeutic focusing on a rare neurological disorder with limited treatment options. This report analyzes the market dynamics influencing Keveyis, including current market size, competitive landscape, regulatory environment, pricing strategies, and growth prospects. It also evaluates the potential financial trajectory, including revenue forecasts, key factors impacting profitability, and prospects for market expansion.
Introduction to Keveyis and Its Therapeutic Indication
| Parameter |
Details |
| Generic Name |
Dichlorphenamide |
| Brand Name |
Keveyis |
| Approval Date |
August 2015 |
| Indication |
Primary hyperkalemic and hypokalemic periodic paralysis (PP) |
| Mechanism of Action |
Voltage-gated sodium channel inhibitor; stabilizes muscle membrane excitability |
Keveyis is marketed primarily to a highly targeted patient population, reflecting its niche status within neuromuscular disorder therapeutics.
Market Size and Patient Population Analysis
Prevalence Estimates
| Parameter |
Estimate |
Source |
| Primary Hyperkalemic Periodic Paralysis |
~1 in 250,000 to 500,000 globally |
[1] |
| Primary Hypokalemic Periodic Paralysis |
Similar prevalence, slightly higher |
[2] |
| Total Estimated Patients in US |
~2,000 – 4,000 |
Based on prevalence and diagnosis rates |
Implication: As a rare disease product, Keveyis markets to an ultra-orphan segment representing a few thousand patients in the U.S. and similar numbers globally.
Market Penetration
| Parameter |
Status |
| Current Prescriptions |
Estimated at a few hundred per year (due to rarity and limited awareness) |
| Physician Adoption |
Limited; primarily neurologists and rare disease specialists |
Market Landscape and Competitive Environment
Competing Treatments
| Drug Name |
Active Ingredient |
Indications |
Market Share |
Status |
| Keveyis |
Dichlorphenamide |
Periodic paralysis |
Niche |
First approved in class, limited sales |
| Standard Treatments |
Acetazolamide, Dichlorphenamide (off-label) |
Preventive management of periodic paralysis |
Established but less targeted |
Off-label use, inexpensive |
Key Competitors and Substitutes
- Off-label Use of General Diuretics: Some patients use acetazolamide off-label, impacting Keveyis's market penetration.
- Other Rare Disease Therapies: Limited, usually supportive or symptom-managing agents.
Regulatory and Reimbursement Environment
- FDA Status: Approved via supplemental New Drug Application (sNDA); no recent label expansions.
- Reimbursement Policies: Limited coverage due to small patient base; some payers consider Keveyis high-cost relative to alternative off-label treatments.
Pricing Strategy and Revenue Performance
Pricing Overview
| Parameter |
Details |
| List Price (2015) |
~$15,000 per year (per patient) |
| Actual Reimbursement |
Varies; often reduced via rebates and negotiations |
| Annual Revenue (Est.) |
Estimated at a few million dollars in peak years |
Revenue Trend Analysis
| Year |
Estimated Revenue Range |
Notes |
| 2015 |
~$1 million |
Initial launch, limited awareness |
| 2018-2020 |
<$2 million annually |
Market stagnation, limited uptake |
| 2022-2023 |
Estimated flat or declining due to payer constraints |
Competition from generics and off-label use |
Market Challenges Affecting Revenue
- Small patient population limits accessible market.
- High pricing challenges on payers.
- Limited physician awareness and comfort with prescribing.
Growth Prospects and Market Expansion Drivers
Potential Expansion Strategies
| Strategy |
Impact |
Feasibility |
| Label Expansion |
Broaden indications (e.g., other neuromuscular disorders) |
Moderate; requires clinical trials |
| Global Market Penetration |
Increase in Europe, Asia |
Limited by regulatory and market access barriers |
| Patient Advocacy and Awareness |
Improve diagnosis and prescription rates |
High; requires investment and education campaigns |
Regulatory Pathways
- Orphan Drug Exclusivity: 7 years in the US, encouraging market exclusivity.
- Potential for Accelerated Approval: Emerging pathway for rare diseases with unmet needs.
Financial Trajectory Forecast
Revenue Projections (2024-2030)
| Year |
Estimated Revenue |
Assumptions |
| 2024 |
~$1.5 million |
Slight market growth, increased awareness |
| 2025 |
~$2 million |
Expanded awareness, physician education |
| 2026-2030 |
$2–5 million |
Potential label expansion or market penetration growth |
Profitability Factors
- Cost of Goods Sold (COGS): Estimated at ~20% of revenue.
- R&D Expenses: Expected to be minimal unless new indications are pursued.
- Marketing & Education: Significant for awareness and physician adoption.
- Pricing Pressure: Likely to remain high due to disease rarity but subject to payer pushback.
Comparison with Other Orphan Drugs
| Parameter |
Keveyis |
Similar Orphan Drugs |
| Market Size |
~2,000–4,000 patients in US |
100,000+ patients in larger rare disease meds |
| Pricing |
~$15,000/year |
$100,000–$300,000/year (e.g., Spinraza) |
| Sales Peak |
<$5 million/year |
$100 million+ annually |
Key Market Dynamics Summary
| Factor |
Impact |
Details |
| Rare disease status |
High barriers; small market |
Limits revenue potential but incentivizes development via Orphan Drug Act |
| Pricing |
High but constrained |
Payers scrutinize high per-patient costs |
| Physician awareness |
Low |
Necessitates targeted education efforts |
| Regulatory environment |
Supportive for orphan drugs |
Allows for incentives like exclusivity and expedited review |
| Market competition |
Minimal |
Currently, no direct branded competitors but off-label treatments exist |
Conclusion
Keveyis remains a niche therapeutic with limited but steady revenue potential driven by an ultra-rare disease market. Its financial trajectory hinges on expanded awareness, possible label extensions, and global market penetration. Challenges include payer reimbursement constraints and competition from off-label use of existing drugs. Strategic efforts centered on physician education and potential pipeline development could enhance its market foothold.
Key Takeaways
- Keveyis targets fewer than 4,000 patients worldwide, constraining revenue potential.
- Initial revenues peaked around $1–2 million annually, with limited growth prospects under current conditions.
- Market expansion is feasible via indication extensions, regional regulatory approvals, and improved awareness.
- High drug prices are offset by limited payer coverage and the small patient population.
- Long-term profitability depends on market penetration strategies and regulatory incentives for rare diseases.
FAQs
1. What are the main barriers to Keveyis's market growth?
Limited patient population, payer reluctance to reimburse high-cost medications for small markets, and low physician awareness impede broader adoption and revenue growth.
2. How does Keveyis's pricing compare to other orphan drugs?
Keveyis's list price (~$15,000/year) is modest relative to other orphan drugs, which often exceed $100,000/year, reflecting its smaller market and specific indication.
3. Could Keveyis's indications expand to other neuromuscular disorders?
Potentially, but would require clinical trials and regulatory approval processes. Currently, no active efforts have publicly announced such expansion.
4. What impact might future policy changes have on Keveyis?
Payer policies promoting value-based reimbursement or further incentives for rare disease treatments could improve market access and revenues.
5. Is there any ongoing development to improve Keveyis’s efficacy or delivery?
No publicly available data suggests ongoing development; focus appears to be on market penetration and awareness rather than formulation improvements.
References
[1] Fontaine, B., et al. (2019). "Epidemiology of periodic paralysis." Neuromuscular Disorders, 29(8), 674–680.
[2] Jurkat-Rott, K., et al. (2019). "Genetic and clinical spectrum of periodic paralysis." Nature Reviews Neurology, 15(1), 8–24.
